Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Zöchbauer-Müller S[au]:

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Scheicher R et al. Blood. (2015)

Retraction: DNA methylation profiles of lymphoid and hematopoietic malignancies. Takahashi T et al. Clin Cancer Res. (2013)

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis. Kollmann K et al. Cancer Cell. (2016)

Search results

Items: 1 to 50 of 62

1.

Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort.

Steindl A, Schlieter F, Klikovits T, Leber E, Gatterbauer B, Frischer JM, Dieckmann K, Widhalm G, Zöchbauer-Müller S, Hoda MAR, Preusser M, Berghoff AS.

J Neurooncol. 2019 Oct;145(1):85-95. doi: 10.1007/s11060-019-03269-x. Epub 2019 Aug 27.

2.

SOCS2 is part of a highly prognostic 4-gene signature in AML and promotes disease aggressiveness.

Nguyen CH, Glüxam T, Schlerka A, Bauer K, Grandits AM, Hackl H, Dovey O, Zöchbauer-Müller S, Cooper JL, Vassiliou GS, Stoiber D, Wieser R, Heller G.

Sci Rep. 2019 Jun 24;9(1):9139. doi: 10.1038/s41598-019-45579-0.

3.

Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer.

Grilz E, Mauracher LM, Posch F, Königsbrügge O, Zöchbauer-Müller S, Marosi C, Lang I, Pabinger I, Ay C.

Br J Haematol. 2019 Jul;186(2):311-320. doi: 10.1111/bjh.15906. Epub 2019 Apr 9.

4.

DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients.

Heller G, Altenberger C, Steiner I, Topakian T, Ziegler B, Tomasich E, Lang G, End-Pfützenreuter A, Zehetmayer S, Döme B, Arns BM, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

J Pathol. 2018 Aug;245(4):387-398. doi: 10.1002/path.5079. Epub 2018 Jun 20.

5.

Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients.

Pavo N, Raderer M, Goliasch G, Wurm R, Strunk G, Cho A, Novak JF, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider ST, Parschalk B, Scheithauer W, Pirker R, Kiesewetter B, Pacher R, Zielinski C, Hülsmann M.

Oncotarget. 2017 Apr 16;8(46):81250-81260. doi: 10.18632/oncotarget.17131. eCollection 2017 Oct 6.

6.

Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery.

Waseda R, Klikovits T, Hoda MA, Hoetzenecker K, Bertoglio P, Dieckmann K, Zöchbauer-Müller S, Pirker R, Prosch H, Döme B, Klepetko W.

J Surg Oncol. 2017 Aug;116(2):227-235. doi: 10.1002/jso.24629. Epub 2017 Apr 13.

PMID:
28407246
7.

SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.

Altenberger C, Heller G, Ziegler B, Tomasich E, Marhold M, Topakian T, Müllauer L, Heffeter P, Lang G, End-Pfützenreuter A, Döme B, Arns BM, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

Mol Cancer. 2017 Jan 5;16(1):1. doi: 10.1186/s12943-016-0568-5.

8.

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.

Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC.

ESMO Open. 2016 Jul 4;1(4):e000066. eCollection 2016.

9.

A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis.

Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M, Schiefer AI, Reichart U, Mayerhofer M, Hoeller C, Zöchbauer-Müller S, Kerjaschki D, Bock C, Kenner L, Hoefler G, Freissmuth M, Green AR, Moriggl R, Busslinger M, Malumbres M, Sexl V.

Cancer Cell. 2016 Aug 8;30(2):359-360. doi: 10.1016/j.ccell.2016.07.003. Epub 2016 Aug 8. No abstract available.

10.

Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG).

Hoda MA, Klikovits T, Arns M, Dieckmann K, Zöchbauer-Müller S, Geltner C, Baumgartner B, Errhalt P, Machan B, Pohl W, Hutter J, Eckmayr J, Studnicka M, Flicker M, Cerkl P, Klepetko W.

Wien Klin Wochenschr. 2016 Sep;128(17-18):618-26. doi: 10.1007/s00508-016-1036-3. Epub 2016 Jul 25.

11.

Lung transplantation in patients with incidental early stage lung cancer-institutional experience of a high volume center.

Klikovits T, Lambers C, Ghanim B, Dome B, Murakoezy G, Zöchbauer-Müller S, Waseda R, Aigner C, Lang G, Taghavi S, Klepetko W, Jaksch P, Hoda MA.

Clin Transplant. 2016 Aug;30(8):912-7. doi: 10.1111/ctr.12764. Epub 2016 Jun 16.

PMID:
27220108
12.

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.

Heller G, Topakian T, Altenberger C, Cerny-Reiterer S, Herndlhofer S, Ziegler B, Datlinger P, Byrgazov K, Bock C, Mannhalter C, Hörmann G, Sperr WR, Lion T, Zielinski CC, Valent P, Zöchbauer-Müller S.

Leukemia. 2016 Sep;30(9):1861-8. doi: 10.1038/leu.2016.143. Epub 2016 May 23.

13.

Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.

Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer-Müller S, Marosi C, Kornek G, Auerbach L, Schneider S, Parschalk B, Scheithauer W, Pirker R, Drach J, Zielinski C, Pacher R.

Heart. 2015 Dec;101(23):1874-80. doi: 10.1136/heartjnl-2015-307848. Epub 2015 Sep 28.

PMID:
26416836
14.

Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.

Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.

J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.

PMID:
26011651
15.

EVI1 promotes tumor growth via transcriptional repression of MS4A3.

Heller G, Rommer A, Steinleitner K, Etzler J, Hackl H, Heffeter P, Tomasich E, Filipits M, Steinmetz B, Topakian T, Klingenbrunner S, Ziegler B, Spittler A, Zöchbauer-Müller S, Berger W, Wieser R.

J Hematol Oncol. 2015 Mar 21;8:28. doi: 10.1186/s13045-015-0124-6.

16.

DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers.

Heller G, Altenberger C, Schmid B, Marhold M, Tomasich E, Ziegler B, Müllauer L, Minichsdorfer C, Lang G, End-Pfützenreuter A, Döme B, Arns BM, Fong KM, Wright CM, Yang IA, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

Oncotarget. 2015 Jan 1;6(1):394-408.

17.

CDK6 as a key regulator of hematopoietic and leukemic stem cell activation.

Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan AS, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Zöchbauer-Müller S, Zuber J, Malumbres M, Kollmann K, Sexl V.

Blood. 2015 Jan 1;125(1):90-101. doi: 10.1182/blood-2014-06-584417. Epub 2014 Oct 23. Erratum in: Blood. 2018 Aug 30;132(9):978-979.

18.

A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis.

Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M, Schiefer AI, Reichart U, Mayerhofer M, Hoeller C, Zöchbauer-Müller S, Kerjaschki D, Bock C, Kenner L, Hoefler G, Freissmuth M, Green AR, Moriggl R, Busslinger M, Malumbres M, Sexl V.

Cancer Cell. 2013 Aug 12;24(2):167-81. doi: 10.1016/j.ccr.2013.07.012. Erratum in: Cancer Cell. 2016 Aug 8;30(2):359-360.

19.

Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.

Berghoff AS, Magerle M, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckman K, Marosi C, Wöhrer A, Hackl M, Zöchbauer-Müller S, Preusser M, Birner P.

APMIS. 2013 Dec;121(12):1144-52. doi: 10.1111/apm.12063. Epub 2013 Jun 12.

PMID:
23756255
20.

ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.

Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Wöhrer A, Hackl M, Zöchbauer-Müller S, von Deimling A, Schoppmann SF, Zielinski CC, Streubel B, Birner P.

Lung Cancer. 2013 Jun;80(3):278-83. doi: 10.1016/j.lungcan.2013.01.019. Epub 2013 Feb 27.

PMID:
23453647
21.

Retraction: DNA methylation profiles of lymphoid and hematopoietic malignancies.

Takahashi T, Shivapurkar N, Reddy J, Shigematsu H, Miyajima K, Suzuki M, Toyooka S, Zöchbauer-Müller S, Drach J, Parikh G, Zheng Y, Feng Z, Kroft SH, Timmons C, McKenna RW, Gazdar AF.

Clin Cancer Res. 2013 Jan 1;19(1):307. doi: 10.1158/1078-0432.CCR-12-3679. Epub 2012 Dec 17. No abstract available.

22.

Genome-wide CpG island methylation analyses in non-small cell lung cancer patients.

Heller G, Babinsky VN, Ziegler B, Weinzierl M, Noll C, Altenberger C, Müllauer L, Dekan G, Grin Y, Lang G, End-Pfützenreuter A, Steiner I, Zehetmayer S, Döme B, Arns BM, Fong KM, Wright CM, Yang IA, Klepetko W, Posch M, Zielinski CC, Zöchbauer-Müller S.

Carcinogenesis. 2013 Mar;34(3):513-21. doi: 10.1093/carcin/bgs363. Epub 2012 Nov 19.

PMID:
23172663
23.

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.

Ghanim V, Herrmann H, Heller G, Peter B, Hadzijusufovic E, Blatt K, Schuch K, Cerny-Reiterer S, Mirkina I, Karlic H, Pickl WF, Zöchbauer-Müller S, Valent P.

Blood. 2012 May 3;119(18):4242-52. doi: 10.1182/blood-2011-09-382770. Epub 2012 Mar 21.

PMID:
22438247
24.

Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers.

Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, Altenberger C, Minichsdorfer C, Lang G, Döme B, End-Pfützenreuter A, Arns BM, Grin Y, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

Clin Cancer Res. 2012 Mar 15;18(6):1619-29. doi: 10.1158/1078-0432.CCR-11-2450. Epub 2012 Jan 26.

25.

Biochip-based detection of KRAS mutation in non-small cell lung cancer.

Kriegshäuser G, Fabjani G, Ziegler B, Zöchbauer-Müller S, End A, Zeillinger R.

Int J Mol Sci. 2011;12(12):8530-8. doi: 10.3390/ijms12128530. Epub 2011 Nov 29.

26.

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer JR, Georgoulias V, Gridelli C, Hirsch FR, Jassem J, Kosmidis P, Krzakowski M, Manegold Ch, Pujol JL, Stahel R, Thatcher N, Vansteenkiste J, Minichsdorfer C, Zöchbauer-Müller S, Pirker R, Zielinski CC; Central European Cooperative Oncology Group (CECOG).

Ann Oncol. 2012 May;23(5):1223-9. doi: 10.1093/annonc/mdr381. Epub 2011 Sep 22.

27.

c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.

Kollmann K, Heller G, Ott RG, Scheicher R, Zebedin-Brandl E, Schneckenleithner C, Simma O, Warsch W, Eckelhart E, Hoelbl A, Bilban M, Zöchbauer-Müller S, Malumbres M, Sexl V.

Blood. 2011 Apr 14;117(15):4065-75. doi: 10.1182/blood-2010-07-299644. Epub 2011 Feb 7.

PMID:
21300982
28.

Lung cancer: from single-gene methylation to methylome profiling.

Heller G, Zielinski CC, Zöchbauer-Müller S.

Cancer Metastasis Rev. 2010 Mar;29(1):95-107. doi: 10.1007/s10555-010-9203-x. Review.

PMID:
20099008
29.

CDK10 is not a target for aberrant DNA methylation in breast cancer.

Heller G, Ziegler B, Brandstetter A, Novak S, Rudas M, Hennig G, Gehrmann M, Acht T, Zöchbauer-Müller S, Filipits M.

Anticancer Res. 2009 Oct;29(10):3939-44.

30.

Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.

Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zöchbauer-Müller S, Kührer I, Mittlböck M, Zwrtek R, Aigner C, Bichler C, Tichy V, Hudec M, Bachleitner T, End A, Müller MR, Roth E, Klepetko W.

J Thorac Cardiovasc Surg. 2008 May;135(5):1036-41. doi: 10.1016/j.jtcvs.2007.10.072.

31.

Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.

Heller G, Schmidt WM, Ziegler B, Holzer S, Müllauer L, Bilban M, Zielinski CC, Drach J, Zöchbauer-Müller S.

Cancer Res. 2008 Jan 1;68(1):44-54. doi: 10.1158/0008-5472.CAN-07-2531.

32.

Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia.

Kainz B, Shehata M, Bilban M, Kienle D, Heintel D, Krömer-Holzinger E, Le T, Kröber A, Heller G, Schwarzinger I, Demirtas D, Chott A, Döhner H, Zöchbauer-Müller S, Fonatsch C, Zielinski C, Stilgenbauer S, Gaiger A, Wagner O, Jäger U.

Int J Cancer. 2007 Nov 1;121(9):1984-93.

33.

Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence.

Schmidt WM, Sedivy R, Forstner B, Steger GG, Zöchbauer-Müller S, Mader RM.

Mol Carcinog. 2007 Sep;46(9):766-72.

PMID:
17538945
34.

[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms].

Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M, Forstner B, Greil R, Jamnig H, Krajnik G, Lang A, Mohn-Staudner A, Schinko H, Studnicka M, Pirker R, Ploner F, Rothmund J, Schiller L, Zabernigg A, Zöchbauer-Müller S.

Wien Klin Wochenschr. 2007;119(7-8):259-66. Review. German. No abstract available.

PMID:
17492355
35.

Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer.

Heller G, Geradts J, Ziegler B, Newsham I, Filipits M, Markis-Ritzinger EM, Kandioler D, Berger W, Stiglbauer W, Depisch D, Pirker R, Zielinski CC, Zöchbauer-Müller S.

Breast Cancer Res Treat. 2007 Jul;103(3):283-91. Epub 2007 Jan 27.

PMID:
17260099
36.

NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma.

Macheiner D, Heller G, Kappel S, Bichler C, Stättner S, Ziegler B, Kandioler D, Wrba F, Schulte-Hermann R, Zöchbauer-Müller S, Grasl-Kraupp B.

J Hepatol. 2006 Jul;45(1):81-9. Epub 2006 Feb 7.

PMID:
16516329
37.

Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas.

Heller G, Fong KM, Girard L, Seidl S, End-Pfützenreuter A, Lang G, Gazdar AF, Minna JD, Zielinski CC, Zöchbauer-Müller S.

Oncogene. 2006 Feb 9;25(6):959-68.

PMID:
16205641
38.

Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation.

Zöchbauer-Müller S, Fong KM, Geradts J, Xu X, Seidl S, End-Pfützenreuter A, Lang G, Heller G, Zielinski CC, Gazdar AF, Minna JD.

Oncogene. 2005 Sep 15;24(41):6249-55.

PMID:
15940253
39.

Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk.

Lewis CM, Cler LR, Bu DW, Zöchbauer-Müller S, Milchgrub S, Naftalis EZ, Leitch AM, Minna JD, Euhus DM.

Clin Cancer Res. 2005 Jan 1;11(1):166-72.

40.

Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors.

Reddy J, Shivapurkar N, Takahashi T, Parikh G, Stastny V, Echebiri C, Crumrine K, Zöchbauer-Müller S, Drach J, Zheng Y, Feng Z, Kroft SH, McKenna RW, Gazdar AF.

Oncogene. 2005 Jan 20;24(4):732-6.

PMID:
15580314
41.

DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies.

Seidl S, Ackermann J, Kaufmann H, Keck A, Nösslinger T, Zielinski CC, Drach J, Zöchbauer-Müller S.

Cancer. 2004 Jun 15;100(12):2598-606.

42.

DNA methylation profiles of lymphoid and hematopoietic malignancies.

Takahashi T, Shivapurkar N, Reddy J, Shigematsu H, Miyajima K, Suzuki M, Toyooka S, Zöchbauer-Müller S, Drach J, Parikh G, Zheng Y, Feng Z, Kroft SH, Timmons C, McKenna RW, Gazdar AF.

Clin Cancer Res. 2004 May 1;10(9):2928-35. Retraction in: Takahashi T, Shivapurkar N, Reddy J, Shigematsu H, Miyajima K, Suzuki M, Toyooka S, Zöchbauer-Müller S, Drach J, Parikh G, Zheng Y, Feng Z, Kroft SH, Timmons C, McKenna RW, Gazdar AF. Clin Cancer Res. 2013 Jan 1;19(1):307.

43.

Fragile histidine triad (FHIT) gene abnormalities in lung cancer.

Zöchbauer-Müller S, Wistuba II, Minna JD, Gazdar AF.

Clin Lung Cancer. 2000 Nov;2(2):141-5.

PMID:
14731325
44.

Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers.

Zöchbauer-Müller S, Lam S, Toyooka S, Virmani AK, Toyooka KO, Seidl S, Minna JD, Gazdar AF.

Int J Cancer. 2003 Nov 20;107(4):612-6.

45.

Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.

Agathanggelou A, Dallol A, Zöchbauer-Müller S, Morrissey C, Honorio S, Hesson L, Martinsson T, Fong KM, Kuo MJ, Yuen PW, Maher ER, Minna JD, Latif F.

Oncogene. 2003 Mar 13;22(10):1580-8.

PMID:
12629521
46.

Future developments in the treatment of lung cancer.

Hirsch FR, Fischer JR, Niklinski J, Zöchbaüer-Müller S.

Lung Cancer. 2002 Dec;38 Suppl 3:S81-5. Review.

PMID:
12468154
47.

Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer.

Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, Shimizu N, Shimizu K, Lee H, Chen CY, Fong KM, Gilcrease M, Roth JA, Minna JD, Gazdar AF.

Int J Cancer. 2003 Jan 10;103(2):153-60.

48.

Aberrant DNA methylation in lung cancer: biological and clinical implications.

Zöchbauer-Müller S, Minna JD, Gazdar AF.

Oncologist. 2002;7(5):451-7. Review.

49.

Molecular pathogenesis of lung cancer and potential translational applications.

Minna JD, Fong K, Zöchbauer-Müller S, Gazdar AF.

Cancer J. 2002 May-Jun;8 Suppl 1:S41-6. Review.

PMID:
12075701
50.

Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.

Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP, Gazdar AF.

Clin Cancer Res. 2002 Feb;8(2):514-9.

Supplemental Content

Loading ...
Support Center